Lall S, Bibile S
Int J Health Serv. 1978;8(2):299-328. doi: 10.2190/GBM9-5W7H-BT8J-VVF3.
This paper describes the experience of Sri Lanka in reforming the structure of production, importation, and distribution of pharmaceuticals in the period 1972-1976. It highlights the actions and reactions of transnational pharmaceutical corporations to these reforms, and traces the achievements and problems of the State Pharmaceuticals Corporation which was set up to implement the reforms. The roles of political leadership in regulating the power of drug transnationals, and of the medical profession in resisting reform, seem to be of crucial significance. Developing countries wishing to lower the present high cost of drug delivery must proceed with great care and immense caution, since complex problems of quality control, bioequivalence, medical acceptance, and consumer reeducation are involved.
本文描述了斯里兰卡在1972年至1976年期间改革药品生产、进口和分销结构的经历。它突出了跨国制药公司对这些改革的行动和反应,并追溯了为实施改革而设立的国家制药公司的成就和问题。政治领导层在规范跨国制药公司权力方面的作用,以及医疗行业在抵制改革方面的作用,似乎至关重要。希望降低目前高昂药品供应成本的发展中国家必须极其谨慎地行事,因为其中涉及质量控制、生物等效性、医学认可和消费者再教育等复杂问题。